Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,205.1
16.6 (0.52%)

 

  • STI Straits Times Index
    3,205.1
    16.6 (0.52%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,588.1
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,126.9
    109.4 (0.42%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,582.6
    -12.2 (-0.34%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,804.8
    96.3 (0.34%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,643.7
    10.8 (0.16%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,256.9M
  • Value: 811.0M
  • Rise: 183
  • Fall: 150
  • Unch: 418

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Hatten Land0.068-0.003
King Wan0.055-0.002
Boldtek0.084+0.020
Sembcorp Marine0.079-0.001
Sinjia Land0.086+0.007
Raffles Edu0.071+0.010
Rex Intl0.345-0.005
ThaiBev0.715+0.010
Shen Yao0.002-0.001
No Signboard0.052-

World Indices

World Indices
Name Last Change
Nasdaq 15,090.2 -125.5
HSI 26,126.9 +109.4
HSCEI 9,356.9 +83.3
Jakarta 6,643.7 +10.8
Nikkei 225 28,804.8 +96.3
SSE Comp 3,582.6 -12.2
Shanghai A 3,754.7 -12.7
Shanghai B 275.7 -1.8
KOSPI 3,006.2 -1.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CYBIN INC CYBIN
Updated on 22 Oct 2021 (End of trading day)
Last (USD): 1.960 Change: -0.020 High: 1.980 Remarks: -
Change (%): -1.01 Low: 1.860
Open 1.950 Yesterday's Close 1.98
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,666,472 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.15263 Trailing EPS (USD) e -0.15263 NAV (USD) b 0.3857
PE a - Trailing PE f - Price / NAV b 5.0817
Dividend (USD) d - Cash In Hand (USD) g 0.2785 Issued & Paid-up Shares c 159,673,000
Dividend Yield (%) d - Price / Cash In Hand g 7.038 Treasury Shares h -
Market Cap (M) 312.959 Enterprise Value (M) 268.483
Piotroski F Score 1 Exchange Code CYBN Par Value ( $ ) n.a.
52 Weeks Volatility (%) n.a. Free Float (%) 78.3
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 16 Aug 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 05 Aug 2021.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CYBIN INC NYSE American 312.959 - - 5.0817 -
Industry Pharmaceuticals: Major NYSE American 321.280 - - 13.6754 -
Local Peer BROOKLYN IMMUNO THERAPEUTICS INC NYSE American 1,043.394 - - 29.6577 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 277.374 - - 48.5795 -
Local Peer ANNOVIS BIO INC NYSE American 234.025 - - 4.8141 -
Local Peer AGEX THERAPEUTICS INC NYSE American 34.261 - - -4.1522 -
Local Peer TIMBER PHARMACEUTICALS INC NYSE American 25.665 - - -13.6472 -
Global Peer JOHNSON & JOHNSON NYSE 430,989.626 29.291 24.105 - 2.431
Global Peer PFIZER INC NYSE 241,984.740 25.165 18.293 3.4548 3.520
Global Peer ELI LILLY AND COMPANY NYSE 233,166.619 37.646 38.409 36.1813 1.214
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 206,730.946 25.611 23.011 3.8254 2.270
Global Peer MERCK & CO INC NYSE 205,420.676 29.068 36.873 6.1699 3.055
Global Peer ABBVIE INC NYSE 192,870.025 42.333 29.272 15.3448 4.430
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 191,442.103 59.901 50.767 12.2124 1.879
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 187,909.086 29.161 26.395 17.9730 1.269
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 127,993.536 - - 3.4773 3.226
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 126,144.845 8.986 18.216 1.6821 2.712
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), INNOVENT BIOLOGICS INC (HKEx), CANSINO BIOLOGICS INC (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), SINOPHARM GROUP CO. LTD. (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), ALLAKOS INC (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO INC (HKEx), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), INNOCARE PHARMA LTD (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), NEKTAR THERAPEUTICS (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), OPKO HEALTH INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), ATAI LIFE SCIENCES NV (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), ERASCA INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ADC THERAPEUTICS SA (NYSE), QUANTERIX CORPORATION (NASDAQ), EVEREST MEDICINES LTD (HKEx), SHANGHAI HENLIUS BIOTECH INC (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), IGM BIOSCIENCES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), SSY GROUP LIMITED (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), CSTONE PHARMACEUTICALS (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), OCUMENSION THERAPEUTICS (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), GENERATION BIO CO (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S A (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), OLEMA PHARMACEUTICALS INC (NASDAQ), IMMUNOTECH BIOPHARM LTD (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), ATEA PHARMACEUTICALS INC (NASDAQ), ABBISKO CAYMAN LTD (HKEx), ICOSAVAX INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), Kimia Farma Tbk. (IDX), PRAXIS PRECISION MEDICINES INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), KRONOS BIO INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), TENAYA THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ANTENGENE CORP LTD (HKEx), MIND MEDICINE (MINDMED) INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PETIQ INC (NASDAQ), ANNEXON INC (NASDAQ), GH RESEARCH PLC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), POINT BIOPHARMA GLOBAL INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), BEYONDSPRING INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), GRITSTONE BIO INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), HUA MEDICINE (HKEx), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PHARVARIS NV (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), MIRUM PHARMACEUTICALS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVOLUS INC (NASDAQ), AC IMMUNE SA (NASDAQ), IGBB (Bursa), PYXIS ONCOLOGY INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), RACE ONCOLOGY LTD (ASX), PYC THERAPEUTICS LIMITED (ASX), EYEPOINT PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), THERATECHNOLOGIES INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), TOT BIOPHARM INTL CO LTD (HKEx), CODIAK BIOSCIENCES INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), FUSION PHARMACEUTICALS INC (NASDAQ), BSTEAD (Bursa), NEXIMMUNE INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), ATHENEX INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), DURECT CORP (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), TCR2 THERAPEUTICS INC (NASDAQ), PHARMA (Bursa), ANGION BIOMEDICA CORP (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), IMMUNIC INC (NASDAQ), OBSEVA SA (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), TRICIDA INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), MUSTANG BIO INC (NASDAQ), IP (SET), PHASEBIO PHARMACEUTICALS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), ALZAMEND NEURO INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), HOOKIPA PHARMA INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), POLYPID LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), NOVAN INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), IX Biopharma (SGX), AYALA PHARMACEUTICALS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), LOGICBIO THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), ODONATE THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), VTV THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), LANTERN PHARMA INC (NASDAQ), GENPREX INC (NASDAQ), LANNETT CO INC (NYSE), KOTRA (Bursa), DARE BIOSCIENCE INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), CRESO PHARMA LTD (ASX), YUMANITY THERAPEUTICS INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), IMARA INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), MANNATECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), ELEDON PHARMACEUTICALS INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), NOVA (Bursa), AYTU BIOPHARMA INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), PAK FAH YEOW INTERNATIONAL (HKEx), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), Hyphens Pharma (SGX), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), EXOPHARM LTD (ASX), ABVC BIOPHARMA INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), BIOHLDG (Bursa), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), INVION LTD (ASX), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), RENOVORX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), BAUDAX BIO INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), MEDLAB CLINICAL LIMITED (ASX), SEQLL INC (NASDAQ), PALLA PHARMA LTD (ASX), ARIDIS PHARMACEUTICAL INC (NASDAQ), PHARMAXIS (ASX), CNS PHARMACEUTICALS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), XORTX THERAPEUTICS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), JCT (SET), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), SUNZEN (Bursa), ONCOSIL MEDICAL LIMITED (ASX), NLS PHARMACEUTICS LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), ACRUX (ASX), PAINREFORM LTD (NASDAQ), IMMURON LIMITED (ASX), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.010
-0.51 %
10 Days --0.140
-6.67 %
20 Days --0.360
-15.52 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 1.680 - 3.220 Change From 1 Year Low +0.280 % Change From 1 Year Low (%) +16.67
Change From 1 Year High -1.260 % Change From 1 Year High (%) -39.13
2 Years Range 1.680 - 3.220 Change From 2 Years Low +0.280 % Change From 2 Years Low (%) +16.67
Change From 2 Years High -1.260 % Change From 2 Years High (%) -39.13
5 Years Range 1.680 - 3.220 Change From 5 Years Low +0.280 % Change From 5 Years Low (%) +16.67
Change From 5 Years High -1.260 % Change From 5 Years High (%) -39.13
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Cybin, Inc. is a biotechnology company that focuses on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. It operates through the following segments: Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Oct 2021 1.950 1.980 1.860 1.960 1,666,472 -
21 Oct 2021 2.050 2.070 1.910 1.980 1,758,159 -
20 Oct 2021 1.940 2.290 1.920 2.020 6,446,163 -
19 Oct 2021 1.940 1.980 1.910 1.920 1,035,682 -
18 Oct 2021 1.960 1.990 1.900 1.940 785,903 -
15 Oct 2021 2.090 2.090 1.890 1.970 1,527,562 -
14 Oct 2021 2.060 2.090 1.980 2.020 771,592 -
13 Oct 2021 2.120 2.120 1.980 2.030 1,096,237 -
12 Oct 2021 2.120 2.150 2.050 2.080 1,011,925 -
11 Oct 2021 2.110 2.150 2.070 2.140 342,167 -
08 Oct 2021 2.130 2.150 2.040 2.100 607,602 -
07 Oct 2021 2.150 2.170 2.110 2.120 871,949 -
06 Oct 2021 2.110 2.150 2.100 2.140 367,273 -
05 Oct 2021 2.200 2.200 2.110 2.150 873,995 -
04 Oct 2021 2.220 2.220 2.100 2.100 574,262 -
01 Oct 2021 2.150 2.200 2.100 2.190 702,273 -
30 Sep 2021 2.230 2.230 2.050 2.190 754,584 -
29 Sep 2021 2.200 2.230 2.120 2.200 464,004 -
28 Sep 2021 2.320 2.350 2.090 2.240 1,472,015 -
27 Sep 2021 2.350 2.350 2.225 2.320 757,607 -
24 Sep 2021 2.430 2.430 2.270 2.320 1,152,495 -
23 Sep 2021 2.250 2.390 2.200 2.330 1,940,224 -
Summary
Current 2 Weeks
(11 Oct 2021 to 22 Oct 2021)
2.110 2.290 1.860 1.960 16,441,862 -
Previous 2 Weeks
(27 Sep 2021 to 08 Oct 2021)
2.350 2.350 1.860 2.100 7,445,564 -
4 Weeks from
(27 Aug 2021 to 24 Sep 2021)
2.290 2.370 1.860 2.320 25,790,285 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.